GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (2)
  • Ciorba, Matthew A.  (2)
  • Nakamura, Mary  (2)
  • 1
    In: Arthritis Care & Research, Wiley, Vol. 74, No. 12 ( 2022-12), p. 1953-1960
    Abstract: Little is known regarding the reactogenicity and related SARS–CoV‐2 vaccine response in patients with chronic inflammatory disease (CID). Our objective was to characterize the adverse event profile of CID patients following SARS–CoV‐2 vaccination and understand the relationship between reactogenicity and immunogenicity of SARS–CoV‐2 vaccines. Methods CID patients and healthy controls eligible to receive messenger RNA (mRNA) SARS–CoV‐2 vaccines participated in 3 study visits (pre‐vaccine, after dose 1, and after dose 2) in which blood and clinical data were collected. Assessment of adverse events were solicited within 7 days of receiving each dose. Serum anti–SARS–CoV‐2 spike IgG ± antibody titers were quantified following vaccination. Statistical analysis was performed utilizing mixed models and tobit regressions, with adjustment for covariates. Results The present study included 441 participants (322 CID patients and 119 control subjects). Compared to controls, CID patients reported greater symptom severity after dose 1 ( P  = 0.0001), including more myalgia and fatigue ( P   〈  0.05). For immunogenicity, a higher symptom severity after dose 1 and a higher number of symptoms after dose 2 was associated with higher antibody titers ( P  ≤ 0.05). Each increase of 1 symptom was associated with a 15.1% increase in antibody titer. Symptom association was strongest with site pain after dose 1 (105%; P  = 0.03) and fatigue after dose 2 (113%; P  = 0.004). Conclusion Patients with CID have a distinct reactogenicity profile following SARS–CoV‐2 vaccination compared to controls. Furthermore, there is an association between increased reactogenicity and increased vaccine response. This finding may speak to the more variable immunogenicity in CID patients and may be an important indicator of vaccine response to the novel SARS–CoV‐2 vaccines.
    Type of Medium: Online Resource
    ISSN: 2151-464X , 2151-4658
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2016713-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Arthritis Care & Research, Wiley, Vol. 75, No. 8 ( 2023-08), p. 1849-1856
    Abstract: Immunocompromised patients with chronic inflammatory disease (CID) may have experienced additional psychosocial burden during the COVID‐19 pandemic due to their immunocompromised status. This study was undertaken to determine if vaccination would result in improved patient‐reported outcomes longitudinally among individuals with CID undergoing SARS–CoV‐2 vaccination regardless of baseline anxiety. Methods Data are from a cohort of individuals with CID from 2 sites who underwent SARS–CoV‐2 vaccination. Participants completed 3 study visits before and after 2 messenger RNA vaccine doses in the initial vaccination series when clinical data were collected. Patient‐reported outcomes were measured using the Patient‐Reported Outcomes Measurement Information System 29‐item Health Profile and expressed as T scores, with 2 groups stratified by high and low baseline anxiety. Mixed‐effects models were used to examine longitudinal changes, adjusting for age, sex, and study site. Results A total of 72% of the cohort was female with a mean ± SD age of 48.1 ± 15.5 years. Overall, sleep disturbance improved following both doses of SARS–CoV‐2 vaccinations, and anxiety decreased after the second dose. Physical function scores worsened but did not meet the minimally important difference threshold. When stratifying by baseline anxiety, improvement in anxiety, fatigue, and social participation were greater in the high anxiety group. Physical function worsened slightly in both groups, and sleep disturbance improved significantly in the high anxiety group. Conclusion Sleep disturbance decreased in a significant and meaningful way in patients with CID upon vaccination. In patients with higher baseline anxiety, social participation increased, and anxiety, fatigue, and sleep disturbance decreased. Overall, results suggest that SARS–CoV‐2 vaccination may improve mental health and well‐being, particularly among those with greater anxiety.
    Type of Medium: Online Resource
    ISSN: 2151-464X , 2151-4658
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2016713-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...